Genitourinary Cancers | Specialty

The OncLive Genitourinary Cancer condition center page is a comprehensive resource for clinical news and expert insights across genitourinary (GU) malignancies, including renal cell carcinoma, urothelial carcinoma, and prostate cancer. This section features news articles, interviews in written and video format, and podcasts that focus on the evolving treatment paradigm of GU cancers and emerging research.

Dr Bowman on Distinctions Between Disease Characteristics and Treatment Response in ccRCC vs Non-ccRCC

May 27th 2025

I. Alex Bowman, MD, discusses the differences in disease presentation between ccRCC and non-ccRCC, as well as standard treatments for these subtypes.

Dr Nguyen on the Evolving Landscape of Adjuvant Therapy in Localized ccRCC

May 27th 2025

Charles B. Nguyen, MD, discusses the evolving landscape of adjuvant therapy in localized clear cell renal cell carcinoma.

Dr Tang on the Implementation of Metastasis-Directed Radiotherapy in Oligometastatic ccRCC

May 23rd 2025

Chad Tang, MD, discusses potential roadblocks for the clinical use of metastasis-directed radiotherapy for patients with oligometastatic ccRCC.

Dr Wang on Key Findings From a Study of the Tumor Microenvironment in ccRCC

May 23rd 2025

Yufei Wang, PhD, discusses how the metastasis of ccRCC could rewire the tumor microenvironment and lead to increased immunosuppression and fibrosis.

Dr Matrana on the Importance of Combination Therapies in Metastatic RCC

May 23rd 2025

Marc R. Matrana, MD, emphasizes the need for combination therapies for the treatment of patients with advanced or metastatic renal cell carcinoma.

Experts Spotlight Noteworthy GU Cancer Abstracts Ahead of the 2025 ASCO Annual Meeting

May 22nd 2025

Ahead of the 2025 ASCO Annual Meeting, experts in genitourinary cancers share the most anticipated research being presented during the meeting.

Dr Tykodi on the Current Limitations of Cabozantinib-Based Triplets in Advanced RCC

May 20th 2025

Scott Tykodi, MD, PhD, discusses the challenges with developing effective, less toxic triplet regimens for patients with advanced RCC.

Combination Regimens Offer Options in Frontline RCC as Novel Agents Advance Through Pipeline

May 19th 2025

During an OncLive Peer Exchange filmed during ASCO GU, expert investigators discussed significant updates in the RCC space.

Dr Hall on Unmet Needs in Later-Line RCC

May 15th 2025

Evan T. Hall, MD, Mphil, discusses several avenues for future research in later-line renal cell carcinoma.

Dr Beckermann on the Rationale for Evaluating Tivozanib/Nivolumab After IO-Based Therapy in RCC

May 14th 2025

Kathryn E. Beckerman, MD, PhD, details the rationale for evaluating tivozanib/nivolumab following immune checkpoint inhibitors in renal cell carcinoma.

Sitravatinib/Nivolumab Shows Modest Activity in Progressive Metastatic Clear Cell RCC Before Trial Termination

May 14th 2025

Sitravatinib plus nivolumab did not produce significant antitumor activity or survival outcomes in patients with progressive metastatic clear cell RCC.

Belzutifan Displays Robust Activity in VHL-Associated RCC

May 12th 2025

Belzutifan was safe and effective in patients with von Hippel-Lindau–associated RCC and other neoplasms.

Limited Role for ICI Rechallenge in RCC Spurs Interest in More Tailored Later-Line Strategies

May 8th 2025

Evan T. Hall, MD, MPhil, discusses the limited potential for immunotherapy rechallenge in patients with RCC and challenges with later-line RCC management.

Giants of Cancer Care® Announces the 13th Annual Class of Inductees

May 7th 2025

OncLive announces the inductees of the 13th annual Giants of Cancer Care recognition program.

Nivolumab/Ipilimumab Meets Primary OS End Point in Non–Clear Cell RCC

May 5th 2025

The combination of nivolumab and ipilimumab was associated with longer 12-month OS vs standard of care in non–clear cell renal cell carcinoma.

Five Under 5: Top Oncology Videos for the Week of 4/27

May 4th 2025

The top 5 OncLive videos of the week cover insights in colorectal cancer, prostate cancer, myeloma, renal cell carcinoma, and urothelial carcinoma.

Mixed Trial Results Underscore Challenges of Adjuvant TKI, IO Regimens in RCC

May 4th 2025

Helen Moon, MD, discusses the current and potential role of TKIs and immunotherapy regimens as adjuvant therapy in renal cell carcinoma.

Dr Hall on the Feasibility of ICI Continuation and Rechallenge Strategies in Second-Line Metastatic RCC

May 2nd 2025

Evan T. Hall, MD, MPhil, discusses the evolving evidence base surrounding ICI continuation and rechallenge strategies in the second-line treatment of metastatic renal cell carcinoma.

Dr Petrylak on the Importance of Early Detection to Minimize Treatment Intensity in Testicular Cancer

April 30th 2025

Testicular Cancer Awareness Month: Early Detection and Risk Assessment Pave the Way Toward Optimal Outcomes

April 30th 2025

Adam Calaway, MD, MPH, highlights the need for early detection and education in testicular cancer.

x